The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1499
Onzetra Xsail - Sumatriptan Nasal Powder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Onzetra Xsail (Avanir), a nasal powder formulation of sumatriptan, for acute treatment of migraine in adults. Nasal spray formulations of sumatriptan (Imitrex) and zolmitriptan (Zomig) have been available for many years.

SUMATRIPTAN FORMULATIONS — Subcutaneously administered sumatriptan relieves pain faster (in about 10 minutes) and more effectively than other triptan formulations, but it causes more adverse effects.1,2 With oral sumatriptan, onset of pain relief generally occurs 45-60 minutes after administration, but patients with migraine who have nausea, vomiting, or gastroparesis may not be able to take or absorb an oral triptan.3 Sumatriptan nasal spray formulations have a more rapid onset of action than oral tablets, but their efficacy also depends on GI absorption (of the significant ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Onzetra Xsail - Sumatriptan Nasal Powder
Article code: 1499b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian